Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IceCure Medical (ICCM)
NASDAQ:ICCM
Holding ICCM?
Track your performance easily
Earnings Data
Report Date
Feb 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.08Last Year’s EPS
-$0.06Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 26, 2024
|% Change Since: 44.14%
|Next Earnings Date:Feb 03, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant growth in sales and improved financial metrics, driven by increased adoption of ProSense and upcoming catalysts, including potential FDA approval. However, challenges remain, including a significant net loss, decreased revenue recognition in Japan, and some uncertainty regarding FDA approval timing.Company Guidance
During IceCure Medical's Q3 2024 earnings call, significant guidance was provided regarding the company's financial performance and future expectations. The company reported a 36% increase in sales of ProSense systems and disposable probes, totaling $2.32 million for the nine months ending September 30, 2024. Total revenues rose by 22% to $2.42 million, while non-GAAP gross profit more than doubled with a 104% increase, and non-GAAP gross margin improved from 27% to 40%. Operating expenses decreased to $12.21 million, and net loss narrowed to $10.84 million compared to $11.66 million for the same period in 2023. The company anticipates the FDA's decision on marketing authorization for ProSense in early-stage breast cancer in Q1 2025, which could significantly enhance U.S. sales. Additionally, they expect Terumo Corporation to file for regulatory approval in Japan in 2025, and they foresee continued publication of third-party data supporting ProSense's efficacy across indications.Significant Sales Growth
ProSense Systems and disposable probe sales increased by 36% to $2.32 million, driven by higher sales in Europe, the U.S., and Japan.
Improved Financial Metrics
Non-GAAP gross profit more than doubled with an increase of 104% and non-GAAP gross margin increased to 40% from 27% compared to the same period last year.
FDA Advisory Panel Approval
Positive outcome from the FDA advisory committee brings IceCure closer to potential marketing authorization for ProSense.
Upcoming Catalysts
Interim results from the ICESECRET study are expected soon, and Terumo Corporation is expected to file for regulatory approval of ProSense for breast cancer in Japan in 2025.
Operational Expense Reduction
Total operating expenses decreased to $12.21 million from $12.89 million, primarily due to reductions in R&D and administrative expenses.
---
ICCM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ICCM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 26, 2024 | $0.78 | $0.79 | +1.28% |
| Aug 20, 2024 | $0.64 | $0.75 | +17.19% |
| May 28, 2024 | $1.03 | $1.04 | +0.97% |
| Apr 03, 2024 | $1.34 | $1.25 | -6.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does IceCure Medical (ICCM) report earnings?
IceCure Medical (ICCM) is schdueled to report earning on Feb 03, 2025, TBA Not Confirmed.
What is IceCure Medical (ICCM) earnings time?
IceCure Medical (ICCM) earnings time is at Feb 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICCM EPS forecast?
ICCM EPS forecast for the fiscal quarter 2024 (Q4) is -$0.08.
---